Suvorexant Guidance for Elderly Patients (≥65 years)

Administration

Efficacy

Safety and Tolerability

Contraindications and Cautions

Guideline Recommendations (American Academy of Sleep Medicine)

Suvorexant Treatment Guidelines for Insomnia

Efficacy and Safety

• The American Academy of Sleep Medicine (AASM) suggests suvorexant primarily for sleep maintenance insomnia with a weak recommendation 3, 4, 5
• At approved doses (≤20 mg), suvorexant reduces wake after sleep onset by 16-28 minutes 6
• At approved doses (≤20 mg), suvorexant improves total sleep time by approximately 10-22 minutes 6
• Suvorexant shows greater efficacy for sleep maintenance than sleep onset at lower doses 3, 5
• At 20 mg, suvorexant demonstrates clinically significant reduction in sleep latency 3, 7
• The most common adverse effect is somnolence, occurring in approximately 7% of patients (vs 3% for placebo) 8